SuperworthRelmada Therapeutics shares outstanding RLMD
Diluted shares outstanding, averaged over each quarter, from 2011.
- Latest quarter, to Jun 30, 2026
- 112.4M
- On a year earlier
- +238.6%
- more shares
Relmada Therapeutics had 112.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 238.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 60.9M | +102% |
| FY2024 | 30.2M | +0% |
| FY2023 | 30.1M | +0% |
| FY2022 | 30.1M | +58% |
| FY2021 | 19.1M | +17% |
| FY2020 | 16.3M | +97% |
| FY2019 | 8.3M | −28% |
| FY2019 | 11.4M | +263% |
| FY2018 | 3.1M | +3% |
| FY2017 | 3M | +1% |
| FY2016 | 3M | +12% |
| FY2015 | 2.7M | +101% |
| FY2013 | 1.3M | +15% |
| FY2012 | 1.2M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 112.4M | +239% | |
| Q1 FY26 | 86.6M | +185% | |
| Q4 FY25 | 60.9M | +102% | |
| Q3 FY25 | 33.2M | +10% | |
| Q2 FY25 | 33.2M | +10% | |
| Q1 FY25 | 30.4M | +1% | |
| Q4 FY24 | 30.2M | +0% | |
| Q3 FY24 | 30.2M | +0% | |
| Q2 FY24 | 30.2M | +0% | |
| Q1 FY24 | 30.1M | +0% | |
| Q4 FY23 | 30.1M | +0% | |
| Q3 FY23 | 30.1M | +0% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Relmada Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.